Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H19N4O7P2S |
Molecular Weight | 425.314 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC2=CN=C(C)N=C2N
InChI
InChIKey=AYEKOFBPNLCAJY-UHFFFAOYSA-O
InChI=1S/C12H18N4O7P2S/c1-8-11(3-4-22-25(20,21)23-24(17,18)19)26-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7H,3-4,6H2,1-2H3,(H4-,13,14,15,17,18,19,20,21)/p+1
Molecular Formula | C12H19N4O7P2S |
Molecular Weight | 425.314 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Cocarboxylase is the coenzyme form of Vitamin B1 present in many animal tissues. Thiamine pyrophosphate (cocarboxylase) is the active form of thiamine, and it serves as a cofactor for several enzymes involved primarily in carbohydrate catabolism. Pancreatic cells obtain thiamin from their surroundings and enzymatically convert it into thiamin pyrophosphate (TPP) in the cytoplasm; TPP is then taken up by mitochondria via a specific carrier the mitochondrial TPP transporter (MTPPT; product of the SLC25A19 gene).
Originator
Sources: https://www.google.com/patents/US2991284 | http://www.jbc.org/content/131/2/597.full.pdf
Curator's Comment: K. Lohmann and Ph. Schuster isolated in 1937 the coenzyme of the carboxylase from yeast in the form of the aneurin-pyrophosphoric acid-ester-chloride. The term cocarboxylase defines the inner salt of the aneurin-pyrophosphoric acid ester.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Branched-chain α-ketoacid dehydrogenase complex Sources: https://www.ncbi.nlm.nih.gov/pubmed/643394 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Cernevit Approved UseThis formulation is indicated as a daily multivitamin maintenance dosage for adults and
children aged 11 years and above receiving parenteral nutrition.
It is also indicated in other situations where administration by the intravenous route is
required. Such situations include surgery, extensive burns, fractures and other trauma,
severe infectious diseases, and comatose states, which may provoke a “stress” situation
with profound alterations in the body’s metabolic demands and consequent tissue
depletion of nutrients.
The physician should not await the development of clinical signs of vitamin deficiency
before initiating vitamin therapy.
This product (administered in intravenous fluids under proper dilution) contributes intake
of these necessary vitamins, except Vitamin K, toward maintaining the body’s normal
resistance and repair processes.
Patients with multiple vitamin deficiencies or with markedly increased requirements may
be given multiples of the daily dosage for two or more days as indicated by the clinical
status. Launch Date1999 |
|||
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Thiamin diphosphate in biological chemistry: exploitation of diverse thiamin diphosphate-dependent enzymes for asymmetric chemoenzymatic synthesis. | 2009 Jun |
|
Thiamine and magnesium deficiencies: keys to disease. | 2015 Feb |
|
Chronic alcohol exposure affects pancreatic acinar mitochondrial thiamin pyrophosphate uptake: studies with mouse 266-6 cell line and primary cells. | 2015 Nov 1 |
|
Ion pair liquid chromatography method for the determination of thiamine (vitamin B1) homeostasis. | 2016 Jan |
|
Thiamine Metabolites and Dementia? | 2016 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/643394
After no added thiamine, the diet was then supplemented with 50. 100 and 150 mg of thiamine-HCL respectively for each of three succeeding weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12014993
Mitochondria were isolated from normal lymphoblasts and were incubated for 15 minutes with various concentrations of radioactive ThDP (Cocarboxylase), ranging from 50 to 200 ug.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:08:54 GMT 2023
by
admin
on
Fri Dec 15 15:08:54 GMT 2023
|
Record UNII |
Q57971654Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
74444-1
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
||
|
DSLD |
445 (Number of products:3)
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
||
|
NCI_THESAURUS |
C45812
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
||
|
LOINC |
3000-7
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
342311
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB06789MIG
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
18290
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
DTXSID2048404
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
Q57971654Y
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
C81632
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
DB01987
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
136-08-3
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
58937
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
9532
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
10459
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
D013835
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
136-09-4
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
ALTERNATIVE | |||
|
45931
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
THIAMINE PYROPHOSPHATE
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
Q57971654Y
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
12318-71-7
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
SUPERSEDED | |||
|
100000085060
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
1358
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY | |||
|
1132
Created by
admin on Fri Dec 15 15:08:54 GMT 2023 , Edited by admin on Fri Dec 15 15:08:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
IONIC MOIETY |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |